Evidence map›Paper›PMID 36647658›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2023

[Zi Huangjing

Hao Wei, Yu Sun, Jun He, Jie-Wei Liu, Ke Xie, Yu-Zhu Zheng, Jiang Zhu

Abstract readMulticenter StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hao WeiDepartment of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.
Yu SunRadiotherapy Physics & Technology Center, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Jun HeDepartment of Oncology, Jiangyou 903 Hospital, Mianyang 621700, China.
Jie-Wei LiuThe Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Ke XieCancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610031, China.
Yu-Zhu ZhengDepartment of Cancer, Chengdu Third People's Hospital, Chengdu 610051, China.
Jiang ZhuDepartment of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To primarily explore the efficacy of Zi Huangjing Methods: This study was designed as a prospective, single-arm, multicenter clinical trial. According to the plan of the study, patients with malignant tumors who had received at least one cycle of chemotherapy and had moderate-to-severe CRF (Piper Fatigue Scale score≥4) were enrolled. All the enrolled patients took Zi Huangjing Results: Eventually, 47 patients completed the entire study. After treatment, the mean score of the Piper Fatigue Scale assessed before the third cycle of chemotherapy (day 42) was 3.21±1.67, which was significantly lower than that at baseline (5.89±1.36) ( Conclusion: According to our preliminary investigation, Zi Huangjing

Indexed as

NeoplasmsQuality of LifeFatigueHumansProspective StudiesCancer-related fatigueChemotherapyQuality of lifeZi HuangjingTM

Identifiers

PMID36647658
PMCPMC10409040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.